Therapeutic Protein

Therapeutic Protein designates biologic medicines composed of proteins engineered or purified for medical use, treating diseases through mechanisms including replacement of deficient proteins, immune modulation, enzymatic activity, or receptor binding. These products include monoclonal antibodies, hormones, cytokines, enzymes, clotting factors, and fusion proteins, offering high specificity and potent biological effects while requiring complex manufacturing and extensive characterisation.

The biopharmaceutical industry has transformed modern medicine through therapeutic proteins addressing conditions previously lacking effective treatments, including autoimmune diseases, cancers, metabolic disorders, and rare genetic diseases. Manufacturing typically employs recombinant expression systems such as CHO cells, yeast, or bacteria, followed by purification processes ensuring high purity and consistent product quality. Product characterisation evaluates structure, glycosylation, aggregation, potency, and stability, as minor variations can affect efficacy, safety, or immunogenicity. Delivery often requires parenteral administration due to protein degradation in the gastrointestinal tract, though formulation advances improve stability and enable more convenient dosing. Regulatory submissions include extensive Chemistry, Manufacturing, and Controls data demonstrating consistent production and quality attributes. As biologics innovation accelerates and novel formats emerge, therapeutic proteins continue expanding as a major drug class supporting targeted, mechanism-driven treatment approaches.